Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055601 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
NCT00055601 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 97 participants.
The verdict
NCT00055601, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of combination chemotherapy plus radiation therapy with or without surgery is more effective in treating bladder cancer. PURPOSE: Randomized phase II trial to study the effectiveness of two combination chemotherapy regimens and radiation therapy with or without radical cystectomy in treating patients who have stage II or stage III bladder cancer.
Interventions
- DRUG Gemcitabine
- DRUG cisplatin
- DRUG paclitaxel
- DRUG fluorouracil
- RADIATION radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2002-12 |
| Est. Completion | 2018-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055601
The ClinicalTrials.gov registry entry for NCT00055601 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Gemcitabine is the first listed.
NCT00055601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00055601 about?
NCT00055601 is a clinical study titled "Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of combination chemotherapy plus radiation therapy with or without surge...
What is the current status of trial NCT00055601?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2002-12. Estimated completion is 2018-05-14.
What interventions are being tested in trial NCT00055601?
The interventions under investigation include: Gemcitabine (DRUG), cisplatin (DRUG), paclitaxel (DRUG), fluorouracil (DRUG), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00055601?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.